Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6536626 | 0.89 | LTB4R (0.51) | LTB4RLTB4R2 | |
| SCHEMBL27570394 | 0.89 | LTB4R (0.49) | LTB4RLTB4R2 | |
| SCHEMBL8569026 | 0.88 | NR1H4 (0.44) | LTB4RLTB4R2 | |
| SCHEMBL7631126 | 0.87 | LTB4R (0.49) | LTB4RLTB4R2 | |
| SCHEMBL8568737 | 0.87 | LTB4R (0.49) | LTB4RLTB4R2 | |
| SCHEMBL8565146 | 0.81 | CNR2 (0.39) | LTB4RLTB4R2 | |
| SCHEMBL8567666 | 0.80 | NR1H4 (0.40) | LTB4RLTB4R2 | |
| SCHEMBL7646400 | 0.78 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL8564636 | 0.78 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL7647502 | 0.76 | LTB4R (0.65) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1390139-A | Oncolytic combinations for the treatment of cancer | LILLY CO ELI (US) | 2003-01-08 | — | — | CN | claimed |
| EP-1231939-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | claimed |
| EP-1231938-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001034198-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034197-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034137-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034135-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| CN-1390139-A | Oncolytic combinations for the treatment of cancer | LILLY CO ELI (US) | 2003-01-08 | — | — | CN | disclosed |
| EP-1231939-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1231938-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034197-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034198-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034135-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034137-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0544488-B1 | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1998-03-11 | — | — | EP | disclosed |
| CN-1035001-C | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1997-05-28 | — | — | CN | disclosed |
| WO-1996036347-A1 | USE OF LEUKOTRIENE ANTAGONISTS FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0743064-A1 | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |